Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 January 2024 | Story Leonie Bolleurs | Photo Supplied
Zola Valashiya
Nearly a decade ago, Zola Valashiya completed his LLB at UFS and is currently working towards his second LLM in Technology and Innovation at the Seattle University School of Law.

Zola Valashiya graduated from the UFS almost ten years ago with an LLB. Since then, amid life’s twists and turns, he obtained an LLM from the University of Washington, secured a job with a successful law firm in the US, and married the love of his life. Currently, Zola is pursuing a second LLM in Technology and Innovation with the Seattle University School of Law.

Following the advice of a dear friend, Zola figured out what drives him and pursued it relentlessly. “This very simple piece of advice taught me the value of my time, and how much power you take back when you prioritise and protect it,” he remarks.

Advancing the greater good

Fast forward nine-plus years since UFS graduation day, Zola works as a strategic adviser at Coopersmith Law + Strategy, a boutique firm in Seattle specialising in health care, global health, gender/racial equality, and climate health.

“The legal work I do involves various tasks, from drafting legal contracts to conducting data analysis, and developing business strategies for deploying new technologies in health systems or addressing climate change. I value this environment because our efforts are focused on advancing the greater good. I have the opportunity to work on projects that I know will benefit individuals, communities, and the planet,” says Zola.

One of the highlights of his career occurred during the pandemic when he played a key role in preserving one of the largest US training programmes for physicians from diverse backgrounds who serve marginalised communities.

He explains, “The pandemic placed a strain on health-care systems worldwide, leading to cost-cutting measures in private hospitals, the termination of community health programmes, and the closure of small clinics in remote areas, in order to recover from the financial losses. However, these programmes and clinics are vital to the communities they serve because the nurses and doctors are often the only health-care providers for miles around. My contributions have helped to ensure the programme’s continuation, and the continued delivery of quality health care to underserved communities.”

Diversifying his skill set

For the future, Zola says he is working towards diversifying his skill set. “The modern-day lawyer needs to know more than just the law. I have learned coding skills, and I am currently focused on expanding my knowledge of artificial intelligence. In so doing, I am equipping myself with the necessary tools and expertise to thrive in this rapidly evolving field, thereby future-proofing my career.

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept